Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 12/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | OGA | O60502 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10316058 | 0.87 | GPR119 (0.66) | GPR119KCNH2KDM4EGAAKMT2A | |
| SCHEMBL10316054 | 0.87 | GPR119 (0.84) | GPR119KCNH2KMT2AALDH1A1 | |
| SCHEMBL10316056 | 0.84 | GPR119 (0.74) | GPR119KCNH2KMT2AOGA | |
| SCHEMBL3619924 | 0.83 | GPR119 (0.58) | GPR119KDM4EGAAKMT2AOGA | |
| SCHEMBL14138626 | 0.82 | GPR119 (0.62) | GPR119KDM4EGAAKMT2AOGA | |
| SCHEMBL10316057 | 0.80 | GPR119 (0.73) | GPR119KCNH2GAAKMT2AOGA | |
| SCHEMBL10276517 | 0.79 | GPR119 (1.00) | GPR119KMT2A | |
| SCHEMBL10316052 | 0.79 | GPR119 (0.71) | GPR119KCNH2KMT2AOGA | |
| SCHEMBL10316053 | 0.78 | GPR119 (0.61) | GPR119KDM4EGAAKMT2AOGA | |
| SCHEMBL3617639 | 0.77 | GPR119 (0.60) | GPR119KDM4EGAAKMT2AOGA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455520-B2 | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-06-04 | — | — | US | disclosed |
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-8445499-B2 | Bipiperidinyl compounds, compositions, containing such compounds and methods of treatment | MERCK SHARP & DOHME CORP. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110039860-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. | 2011-02-17 | — | — | US | disclosed |
| US-20110003849-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2011-01-06 | — | — | US | disclosed |
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME LLC | 2010-08-05 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK SHARP & DOHME CORP. | 2010-02-04 | — | — | US | disclosed |
| WO-2008085316-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | MERCK & CO., INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197691-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GPR119 149/4885KCNH2 1674/4885KDM4E 3299/4885 |
| US-20110003849-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GPR119 136/4885KCNH2 1729/4885KDM4E 3239/4885 |
| US-20100029688-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885KCNH2 1186/4885KDM4E 4611/4885 |
| US-20110039860-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | EPHX1, EPHX2, PTGIS | GPR119 224/4885KCNH2 1913/4885KDM4E 2946/4885 |
| US-20120178681-A1 | BIPIPERIDINYL COMPOUNDS, COMPOSITIONS, CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT | GPR119, GPR139, GPR27 | GPR119 1/4885KCNH2 1063/4885KDM4E 4616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.